. home.aspx

NEWS

home.aspx
   


FDA approves expanded use of Novartis’ lung cancer drug Zykadia

May 30, 2017 / Niamh Marriott
SHARESHARESHARE

The US Food and Drug Administration (FDA) approved the expanded use of Novartis’ Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.